A new study published by the Science Translational Medicine journal showed that, for a small cohort, LMB-100 could be even more effective when paired with Keytruda for treating patients with mesothelioma. Researchers saw a median survival rate of almost a year, with a handful of clinical trial participants continuing to show progress after more than three years. Following this success, the National Cancer Institute is currently accepting clinical trial participants for phase 2 of the study. LMB-100 is an immunotoxin drug designed to help the immune system find and destroy cancer and mesothelioma cells. Keytruda, an antibody drug used in […]
The post New Study Shows LMB-100 Can Be Even More Effective Paired with Keytruda for Mesothelioma Treatment appeared first on Mesothelioma Help Cancer Organization.
from Blog – Mesothelioma Help Cancer Organization https://ift.tt/3iPCl2N
via IFTTT
No comments: